Approval · Notice of Compliance 18553 · 2016
RISPERDAL CONSTA: Notice of Compliance 18553
Issued October 11, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18553
- Date
- October 11, 2016
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change to the drug product manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RISPERDAL CONSTA | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE 15.5 MG per VIAL
- RISPERIDONE 29.7 MG per VIAL
- RISPERIDONE 44.1 MG per VIAL
- RISPERIDONE 57.8 MG per VIAL